Restriction with Normal Spirometry: A Retrospective Cohort Study

Alexander T. Moffett,[1,2,3] Aparna Balasubramanian,[4] Meredith C. McCormack,[4] Gary E. Weissman[1,2,3,5]

[1]Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA

[2]Palliative and Advanced Illness Research (PAIR) Center, University of Pennsylvania, Philadelphia, PA, USA

[3]Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, PA, USA

[4]Division of Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, MD, USA

[5]Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, PA, USA

Corresponding Author

Alexander T. Moffett
Hospital of the University of Pennsylvania
Division of Pulmonary, Allergy, and Critical Care Medicine
3400 Spruce Street
Philadelphia, PA 19104
amoffett@upenn.edu

ORCID IDs

0000-0001-8490-4899 (ATM), 0000-0002-1854-6672 (AP), 0000-0003-1702-3201 (MCM), 0000-0001-9588-3819 (GEW)

Manuscript Word Count: 3200 / 3200

Abstract Word Count: 300 / 300

References: 46 / 50

Tables: 2

Figures: 3

Abstract

Background

Though a normal forced vital capacity (FVC) is typically thought to imply the absence of restriction, recent data suggest that restriction may in fact be common among patients with normal spirometry. However, the clinical significance of restriction with normal spirometry is unknown.

Research Question

What clinical characteristics and outcomes are associated with restriction with normal spirometry?

Study Design and Methods

We interpreted pulmonary function tests (PFTs) with both static and dynamic lung volume measurements performed between 2012 and 2025 at four pulmonary diagnostic labs. We used multivariable logistic regression to identify clinical characteristics associated with restriction among patients with normal spirometry and used a Cox proportional hazards model to assess the association of restriction with survival, adjusting for age, sex, forced expiratory volume in 1 second (FEV_1) z-score, FVC z-score, and FEV_1/FVC z-score.

Results

We interpreted 83,886 PFTs from 47,597 patients (mean age 58.8 years, 59.8% female, 63.6% White). The prevalence of restriction among patients with normal spirometry was 25.7% Restriction with normal spirometry was more likely in older patients (adjusted odds ratio [aOR] 1.01 per year, 95% CI 1.01–1.01), in non-White patients (aOR 1.33, 95% CI 1.26–1.41), and in patients with a diagnosis (aOR 3.65, 95% CI 3.43–3.88) or radiographic evidence (aOR 3.02, 95% CI 2.79–3.28) of interstitial lung disease (ILD). Restriction with normal spirometry was less likely among female patients (aOR 0.64, 95% CI 0.60–0.67), and patients with a diagnosis (0.74, 95% CI 0.67–0.82) or radiographic evidence (aOR 0.81, 95% CI 0.73–0.89) of chronic obstructive pulmonary disease. Restriction with normal

spirometry was associated with increased all-cause mortality (adjusted hazard ratio 1.45, 95% CI 1.34–1.57) as compared to normal spirometry without restriction.

Interpretation

Restriction with normal spirometry is associated with ILD and with decreased survival. Clinically significant ventilatory impairments are common in patients with normal spirometry.

Key Words

pulmonary function test interpretation; restriction; spirometry

Abbreviations

BMI = body mass index; COPD = chronic obstructive pulmonary disease; D_{LCO} = diffusing capacity of carbon monoxide; FEV_1 = forced expiratory volume in 1 second; FVC = forced vital capacity; GLI = Global Lung Function Initiative; ILD = interstitial lung disease; K_{CO} = transfer coefficient for carbon monoxide; PFT = pulmonary function test; RV = residual volume; TLC = total lung capacity.

Introduction

A central purpose of pulmonary function test (PFT) interpretation is to determine the presence or absence of restriction.[1–3] The European Respiratory Society and American Thoracic Society (ERS/ATS) technical standard on pulmonary function test (PFT) interpretation defines restriction by a total lung capacity (TLC) less than the lower limit of normal (LLN).[4] According to this technical standard, while static lung volumes are necessary to determine the presence of restriction, the absence of restriction can nonetheless be inferred from spirometry alone if the forced vital capacity (FVC) is greater than the LLN.[4,5]

In support of this recommendation, the technical standard cites a single study which estimated the prevalence of restriction among patients with normal spirometry to be 2.4%.[6] This study, however, was performed at a single site, was limited to White patients, involved fewer than two thousand PFTs, and employed race-specific reference equations that are no longer recommended by ERS/ATS.[7] While other single-site studies using race-specific reference equations have reported similar prevalence estimates,[8–14] a recent multi-site study using race-neutral reference equations instead estimated the prevalence of restriction among patients with normal spirometry to be 19.5%.[15]

Although restriction with normal spirometry may be more common than previously reported, its clinical significance remains unknown. Among patients with normal spirometry how do those with restriction compare to those without restriction? What events are associated with restriction with normal spirometry? Does this interpretation persist on repeat pulmonary function testing? To address these questions, we performed a retrospective cohort study to assess the clinical significance of restriction with normal spirometry by identifying the clinical characteristics and events with which it is associated.

Study Design and Methods

Study Design

This retrospective cohort study was performed in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines for reporting observational studies (**e-Table 1**).[16] The University of Pennsylvania Institutional Review Board approved this study.

Study Population

We included PFTs with both static and dynamic lung volume measurements that were performed between January 2012 and July 2025 at one of four pulmonary diagnostic labs within a single university health system. We excluded PFTs with missing demographic or anthropometric data, as well as those from patients less than 18 years of age or more than 80 years of age at the time of testing. We followed patients from their first encounter in the electronic health record until July 2025.

Pulmonary Function Tests

The PFTs included in this study were performed as part of routine clinical practice in accordance with ATS recommendations.[17–21] Static lung volumes were measured with plethysmography. PFTs were interpreted in accordance with the current ERS/ATS technical standard.[4] The FVC z-score and the forced expiratory volume in 1 second to FVC (FEV_1/FVC) z-score were calculated with Global Lung Function Initiative (GLI) Global reference equations.[22] TLC z-scores, D_{LCO}, and K_{CO} z-scores were calculated with GLI equations.[23,24] A PFT parameter was defined as abnormal if its z-score was less than -1.645, and as normal otherwise. Restriction with normal spirometry was defined by a normal FVC, a normal FEV_1/FVC, and an abnormal TLC. Restriction with abnormal spirometry was defined by an abnormal FVC, a normal FEV_1/FVC, and an abnormal TLC.

Clinical Characteristics

Patient age, sex, and body mass index (BMI) were as documented on the PFT report. Patient race and ethnicity were as documented in the electronic health record (EHR). The presence of respiratory symptoms was assessed at the time of pulmonary function testing and documented in structured fields in the PFT report. Cough was present if the patient endorsed a productive or non-productive cough. Dyspnea was present if the patient endorsed dyspnea on hills and stairs, with walking, or with any exertion. Wheezing was present if the patient endorsed rare, frequent, or constant wheezing.

We used multimodal automated phenotyping (MAP)—an unsupervised method that has been previously validated for asthma and chronic obstructive pulmonary disease (COPD)—to label patients for the presence or absence of different types of respiratory diseases.[25] Respiratory disease types were drawn from the 2005 ATS/ERS guidelines for PFT interpretation.[26] For each patient and each type of respiratory disease, we calculated the number of outpatient clinical encounters for the patient in which an International Classification of Disease (ICD) code associated with the disease was assigned (**e-Tables 2**), the total number of references to the disease in the patient's outpatient progress notes using regular expressions (**e-Table 3**), and the total number of outpatient encounters for the patient. With these inputs, the MAP algorithm was then used to predict the presence or absence of each respiratory disease for each patient.[25]

We used natural language processing with regular expressions to determine whether, prior to the performance of each PFT, a chest computed tomograph (CT) had been performed in which findings consistent with interstitial lung disease (ILD) or COPD were referenced in the impression (**e-Table 4**). Regular expressions were also used to classify the respiratory effort associated with spirometry, using the comments of respiratory technicians to determine the presence of adequate or inadequate effort (**e-Table 5**).

Logistic regression was used to compare the odds of each of the above characteristics among PFTs with normal spirometry with and without restriction. Adjusted and unadjusted

analyses were performed, with the former including age, sex, FEV_1 z-score, FVC z-score, and FEV_1/FVC z-score as covariates.

In a secondary analysis, we compared the odds of these characteristics in PFTs with restriction with and without normal spirometry. In this secondary analysis, the adjusted analysis included age, sex, and TLC z-score as covariates.

Events

In patients with normal spirometry we compared the time from PFT performance to an emergency department (ED) visit with a respiratory complaint (**e-Table 6**) and to mortality from any cause, in patients with and without restriction. Adjusted and unadjusted analyses were performed with Cox proportional hazards models, with age, sex, FEV_1 z-score, FVC z-score, and FEV_1/FVC z-score as covariates.

Repeat Testing

To assess the persistence of restriction with normal spirometry on repeat testing, we identified patients with this interpretation on their initial PFT, and compared this interpretation to the interpretation of subsequent PFTs. We also identified all PFTs with follow up testing and calculated the prevalence of pairs of interpretations on initial and repeat testing.

Sensitivity Analysis

To assess the sensitivity of our findings to the adoption of race-neutral reference equations, we repeated our analysis with the race-specific GLI 2012 reference equations.[27]

Statistical Computing

The analysis was performed with R version 4.5.1. The MAP algorithm was implemented with the MAP package.[28] All statistical tests were two sided and a P value < 0.05 was

interpreted as statistically significant. All code is open source and publicly accessible (https://github.com/weissman-lab/restriction-with-normal-spirometry).

Results

We interpreted 83,886 PFTs from 47,597 patients (**Table 1**, **e-Figure 1**). Most PFTs were from female (50,196 [59.8%]) and from White (50,859 [63.6%]) or Black (23,495 [29.4%]) patients. The mean age was 58.8 years (standard deviation [SD] 14.0). The mean FVC, FEV_1/FVC, and TLC z-scores were −1.0 (SD 1.4), −0.7 (SD 1.4), and −1.3 (SD 1.6), respectively. FVC and TLC z-scores were lower among patients aged 41–65, male patients, and non-White patients (**e-Table 7–9**). There was significant variation in pulmonary function across the four different pulmonary diagnostic labs (**e-Table 10**). The median follow-up time was 32 (interquartile range 63) months. Pack years, symptoms, imaging, and bronchodilator response data were missing for a significant fraction of PFTs (**e-Table 11**).

Among patients with normal spirometry, the prevalence of restriction was 25.7% (95% CI 25.3–26.1) (**Figure 1**). Restriction of any form was present in 32,589 (38.8%, 95% confidence interval [CI] 38.5%–39.2%) PFTs. Restriction with normal spirometry was present in 11,361 (13.5%, 95% CI 13.3–13.8) PFTs, while restriction with abnormal spirometry was present in 17,194 (20.5%, 95% CI 20.2–20.8) PFTs, and a mixed ventilatory impairment was present in 4,034 (4.8%, 95% CI 4.7–5.0) PFTs. The median TLC z-score among PFTs with restriction with normal spirometry was −2.2 (first quartile −2.6, third quartile −1.9) (**Figure 2**).

Among PFTs with normal spirometry, restriction was more likely in older patients (adjusted odds ratio [aOR] 1.01 per year, 95% CI 1.01–1.01), in more obese patients (aOR 1.00 per kg/m², 95% CI 1.00–1.01), in Black patients (aOR 1.35, 95% CI 1.26–1.43), in patients with chronic cough (aOR 1.21, 95% CI 1.11–1.33) or dyspnea (aOR 1.15, 95% CI 1.04–1.26), and in patients with ILD (aOR 3.65, 95% CI 3.43–3.88) or evidence of ILD on chest CT (aOR 3.02, 95% CI 2.79–3.28) (**Table 2**). Restriction was less likely in female patients (aOR 0.64, 95% CI 0.60–0.67), in patients with wheezing (aOR 0.84, 95% CI 0.76–0.93),

in patients with chronic obstructive pulmonary disease (aOR 0.74, 95% CI 0.67–0.82) or evidence of COPD on chest CT (aOR 0.81, 95% CI 0.73–0.89), in patients with a positive bronchodilator response (aOR 0.38, 95% CI 0.28–0.52), and in patients with increased residual volume (RV) (aOR 0.01 per SD, 95% CI 0.01–0.01), increased D_{LCO} (aOR 0.61 per SD, 95% CI 0.60–0.62) or increased K_{CO} (aOR 0.81 per SD, 95% CI 0.79–0.83). Restriction was not associated with adequacy of effort on spirometry (aOR 0.83, 95% CI 0.46–1.56)

Among PFTs with restriction, normal spirometry was more likely in patients with a diagnosis of ILD (aOR 1.95, 95% CI 1.84–2.07) or evidence of ILD on chest CT (aOR 1.89, 95% CI 1.74–2.05) (**e-Table 12**).

Restriction with normal spirometry was present on the initial PFTs of 5,346 patients and was still present on 922 (54.0%, 95% CI 51.6–56.4), 539 (55.3%, 95% CI 52.1–58.4), 379 (54.1%, 95% CI 50.4–57.9), and 273 (54.4%, 95% CI 49.9–58.8) patients on their second, third, fourth, and fifth PFTs, respectively (**Figure 3a**). Among PFTs with follow up testing, restriction with normal spirometry was present in 3,670 (62.9%, 95% CI 61.7–64.2) tests, while 1,095 (18.8%, 95% CI 17.8–19.8) were normal, 792 (13.6%, 95% CI 12.7–14.5) were restrictive with abnormal spirometry, and 153 (2.6%, 95% CI 2.2–3.1) tests were mixed (**Figure 3b**).

Among PFTs with normal spirometry, restriction was associated with an increased risk of an emergency department visit with a respiratory complaint (adjusted hazard ratio [aHR] 1.18, 95% CI 1.11–1.26) and with increased all-cause mortality (aHR 1.45, 95% CI 1.34–1.57).

In our sensitivity analysis, the odds of restriction with normal spirometry were significantly higher in non-White patients when using race-specific reference equations (**e-Table 13**). Race-specific reference equations did not have a significant impact on the prevalence of restriction with normal spirometry, on its persistence on repeat testing (**e-Figure 2**), or on its association with ED visits or all-cause mortality (**e-Table 14**).

Discussion

In this retrospective cohort study involving more than 80,000 PFTs performed at four pulmonary diagnostic labs, restriction was present in more than 1 in 4 PFTs with normal spirometry, and was associated with both ILD and increased mortality. The prevalence of restriction among patients with normal spirometry and the close association of such restriction with ILD indicates that clinically significant ventilatory impairments are common among patients with normal spirometry.

Our study challenges the approach to PFT interpretation recommended by the ERS/ATS technical standard, in which the presence of a normal FVC is used to infer the absence of restriction.[4,5] In our cohort, the prevalence of restriction among patients with normal spirometry was 26.4%, more than an order of magnitude greater than the prevalence of 2.4% cited by ERS/ATS in support of the current recommended interpretive approach.[6] The use of a normal FVC to exclude restriction would have resulted in the misclassification of more than 1 in 4 PFTs with normal spirometry and the failure to identify more than 1 in 3 PFTs with restriction. Our study suggests that the use of a normal FVC to exclude restriction may result in the inaccurate classification of pulmonary physiology in a significant percentage of patients with normal spirometry.

Moreover, our study suggests that such misclassification has important clinical implications, as restriction with normal spirometry is associated with distinct clinical characteristics. Among patients with normal spirometry, those with restriction were more likely to be diagnosed with ILD, to have evidence of ILD on chest CT, and to have a reduced D_{LCO}, They were less likely to be diagnosed with asthma or COPD, to have evidence of COPD on chest CT, or to have a positive bronchodilator response. Among patients with restriction, those with normal spirometry were more likely to be diagnosed with ILD and to have evidence of ILD on chest CT than those with abnormal spirometry. It is not simply that respiratory disease can be seen in patients with normal spirometry, but instead that, in the right clinical setting, normal spirometry can itself indicate a higher probability of respiratory disease. Given the close association of restriction with normal spirometry with

ILD, our study suggests that normal spirometry should not be used to exclude ILD, with such exclusion resulting in diagnostic error and delay.[29,30]

Three possible mechanisms may contribute to restriction with normal spirometry. First, restriction with normal spirometry may stem from a reduced RV. As the TLC is equal to the sum of the vital capacity and the RV, a reduced RV allows for the combination of a normal FVC and an abnormal TLC. In our cohort, the RV was significantly lower in patients with restriction with normal spirometry than in patients with normal spirometry without restriction, with a z-score of -1.1 in the former and 0.3 in the latter. In this respect, restriction with normal spirometry can be seen as the obverse of the non-specific pattern, in which the FVC is abnormal, while the the FEV_1/FVC and TLC are normal.[31,32] In the case of the non-specific pattern, an increased RV allows for the combination of both an abnormal FVC and a normal TLC.

Second, restriction with normal spirometry may stem from differences in the cohorts used to define reference equations for the FVC and TLC.[7,33] While the GLI Global equations for dynamic lung volumes are based on a global cohort of healthy White, Black, North and South East Asian individuals, the GLI equations for static lung volumes are based on a cohort of healthy White individuals drawn primarily from Europe.[22,24] If the lung function of the latter cohort were greater than that of the former—as would be expected given the effect that socioeconomic factors have on lung function even among healthy volunteers—this would lead to a discordance in the TLC and FVC LLN, resulting in a greater number of patients with both a normal FVC and an abnormal TLC than if these equations had been defined with the same cohort.[34–37] In the absence of global race-neutral reference equations for static lung volumes, the precise contribution of such discordance to the prevalence of restriction with normal spirometry is unclear. Nonetheless, the close association between restriction with normal spirometry and ILD suggests that restriction with normal spirometry represents more than just a statistical artifact related to the use of discordant reference equations.

Third, restriction with normal spirometry may result from errors in static or dynamic lung volume measurement, as these values are obtained from different maneuvers with

different assessments of technical adequacy.[38–40] Nonetheless, if this were the primary mechanism responsible for the findings in this study, we would expect to see a greater degree of variability of interpretation on repeat pulmonary function testing. Moreover, among patients with normal spirometry, we did not find an association between restriction and the documentation of concerns regarding spirometric effort.

Our study also has important implications for the equity of PFT interpretation, as the higher prevalence of restriction with normal spirometry among non-White patients indicates that the interpretation of PFTs from non-White patients is less likely to be accurate than it is for PFTs from White patients. In our unadjusted analysis, restriction with normal spirometry was more than twice as likely among Black patients than it was among White patients. As restriction with normal spirometry is more likely in patients with FVC z-scores near the lower limit of normal, the prevalence of restriction with normal spirometry was greater among Black patients, who in our cohort had significantly lower FVC z-scores than patients of other races.[15] While much of this difference resolved when correcting for baseline differences in spirometry, such correction is not applied in practice. Notably, this difference was present despite our use of race-neutral reference equations. In our sensitivity analysis, race-specific reference equations were associated with an even greater differences, with the unadjusted odds of restriction more than 4 times greater in Black patients, and the adjusted odds more than 8 times greater. Though these findings offer yet another reason to adopt race-neutral reference equations, while these equations may reduce such bias, they do not eliminate it entirely.[41–44]

While out study challenges the approach to PFT interpretation recommended by ERS/ATS, the proper response to this challenge remains to be determined. One possible response would be to incorporate restriction with normal spirometry into PFT interpretation as a distinct pattern, something analogous to preserved ratio impaired spirometry (PRISm).[45] Another possible response would be to see the prevalence of restriction with normal spirometry not as something to be accepted but instead as a reason to reform the current approach to PFT interpretation, reducing the prevalence of restriction with normal spirometry by increasing the FVC z-score cutoff used to define normal spirometry. The use of the fifth percentile as a cutoff to define normal spirometry is merely a convention and a

more conservative approach to the identification of normal spirometry may be indicated if the current cutoff obscures the presence of clinically significant respiratory impairments. The proper response will depend upon the determination of the costs associated with failing to identify restriction and the benefits of avoiding the need for static lung volume measurements.

Strengths and Limitations

This study has several strengths. First, we offer the first assessment of the clinical characteristics of patients with restriction with normal spirometry. Second, we include the interpretation of more than 80,000 PFTs performed at four different pulmonary diagnostic labs. Third, we use EHR data to assess clinical diagnoses, with the MAP algorithm allowing greater accuracy than would be possible with only ICD code data.

This study also has important limitations. First, as our cohort was limited to PFTS with both static and dynamic lung volume measurements, there is the potential for ascertainment bias. Restriction with normal spirometry is primarily a concern when pulmonary function testing includes only dynamic lung volume measurement, and differences in this patient population may limit the external validity of our findings. Second, as this was a retrospective cohort study using EHR data, our cohort had a significant amount of missing data, suggesting the potential for selection bias.[46] Third, while we included PFTs from four pulmonary diagnostic labs, all labs were within a single health system. Moreover, prevalence of both restriction and ILD were higher in our cohort than has been reported in other studies of PFT interpretation. It will be important to confirm our findings in future prospective studies involving different cohorts.

Interpretation

Restriction with normal spirometry is more common than has been previously reported and is associated with ILD and with decreased survival. Clinically significant ventilatory impairments are common among patients with normal spirometry.

Acknowledgements

Contributions

ATM participated in study design and analysis, drafted and revised the manuscript, and is the guarantor of this work. AB, MCM, and GEW contributed to study design and revised the manuscript. All authors have read and approved the manuscript.

Funding

ATM reports funding from NHLBI F32 HL167456. GEW reports funding from NHLBI R03 HL171424 and NIGMS R35 GM155262.

Disclosures

ATM, AB, and GEW have no financial disclosures to report relevant to this manuscript. MCM has received royalties from UpToDate, and consulting income from GlaxoSmithKline, Boehringer Ingelheim, Aridis, MCG Diagnostics and NDD Medical Technologies.

References

1. Crapo RO. Pulmonary-function testing. *N Engl J Med.* 1994;331(1):25-30.

2. Kaminsky DA, Irvin CG, eds. *Pulmonary Function Testing: Principles and Practice.* Springer; 2018.

3. Scanlon PD, Hyatt RE. *Hyatt's Interpretation of Pulmonary Function Tests.* Fifth Edition. Wolters Kluwer; 2020.

4. Stanojevic S, Kaminsky DA, Miller MR, et al. ERS/ATS technical standard on interpretive strategies for routine lung function tests. *Eur Respir J.* 2022;60(1):2101499.

5. MacIntyre NR, Bhakta NR, Stanojevic S, et al. Translating pulmonary function test results into practical clinical interpretations. *Ann Am Thorac Soc.* 2025;22(11):1633-1640.

6. Aaron SD, Dales RE, Cardinal P. How accurate is spirometry at predicting restrictive pulmonary impairment?. *Chest.* 1999;115(3):869-873.

7. Bhakta NR, Bime C, Kaminsky DA, et al. Race and ethnicity in pulmonary function test interpretation: an official American Thoracic Society statement. *Am J Respir Crit Care Med.* 2023;207(8):978-995.

8. Glady CA, Aaron SD, Lunau M, Clinch J, Dales RE. A spirometry-based algorithm to direct lung function testing in the pulmonary function laboratory. *Chest.* 2003;123(6):1939-1946.

9. Swanney MP, Beckert LE, Frampton CM, Wallace LA, Jensen RL, Crapo RO. Validity of the American Thoracic Society and other spirometric algorithms using

FVC and forced expiratory volume at 6 s for predicting a reduced total lung capacity. *Chest.* 2004;126(6):1861-1866.

10. Vandevoorde J, Verbanck S, Schuermans D, et al. Forced vital capacity and forced expiratory volume in six seconds as predictors of reduced total lung capacity. *Eur Respir J.* 2008;31(2):391-395.

11. Venkateshiah SB, Ioachimescu OC, McCarthy K, Stoller JK. The utility of spirometry in diagnosing pulmonary restriction. *Lung.* 2008;186(1):19-25.

12. Scarlata S, Pedone C, Conte ME, Incalzi RA. Accuracy of spirometry in diagnosing pulmonary restriction in elderly people: diagnosting pulmonary restriction in elderly people. *J Am Geriatr Soc.* 2009;57(11):2107-2111.

13. Khalid I, Morris ZQ, Khalid TJ, Nisar A, Digiovine B. Using spirometry to rule out restriction in patients with concomitant low forced vital capacity and obstructive pattern. *Open Respir Med J.* 2011;5:44-50.

14. Bruel Tronchon N, Frappé E, Chomette Ballereau S, Barthélémy JC, Costes F. Prediction of pulmonary restriction from forced vital capacity in elderly is similar using GLI and ERS equations. *Lung.* 2014;192(5):775-779.

15. Moffett AT, Balasubramanian A, McCormack MC, Aysola J, Halpern SD, Weissman GE. A normal forced vital capacity does not reliably or equitably exclude restriction. *Ann Am Thorac Soc.* 2025;22(9):1440-1443.

16. Elm E von, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. *PLoS Med.* 2007;4(10):e296.

17. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. *Eur Respir J.* 2005;26(2):319-338.

18. Wanger J, Clausen JL, Coates A, et al. Standardisation of the measurement of lung volumes. *Eur Respir J.* 2005;26(3):511-522.

19. Graham BL, Brusasco V, Burgos F, et al. 2017 ERS/ATS standards for single-breath carbon monoxide uptake in the lung. *Eur Respir J.* 2017;49(1):1600016.

20. Graham BL, Steenbruggen I, Miller MR, et al. Standardization of spirometry 2019 update. An official American Thoracic Society and European Respiratory Society technical statement. *Am J Respir Crit Care Med.* 2019;200(8):e70-e88.

21. Bhakta NR, McGowan A, Ramsey KA, et al. European Respiratory Society/American Thoracic Society technical statement: standardisation of the measurement of lung volumes, 2023 update. *Eur Respir J.* 2023;62(4):2201519.

22. Bowerman C, Bhakta NR, Brazzale D, et al. A race-neutral approach to the interpretation of lung function measurements. *Am J Respir Crit Care Med.* 2023;207(6):768-774.

23. Stanojevic S, Graham BL, Cooper BG, et al. Official ERS technical standards: Global Lung Function Initiative reference values for the carbon monoxide transfer factor for Caucasians. *Eur Respir J.* 2017;50(3):1700010.

24. Hall GL, Filipow N, Ruppel G, et al. Official ERS technical standard: Global Lung Function Initiative reference values for static lung volumes in individuals of European ancestry. *Eur Respir J.* 2021;57(3):2000289.

25. Liao KP, Sun J, Cai TA, et al. High-throughput multimodal automated phenotyping (MAP) with application to PheWAS. *J Am Med Inform Assoc.* 2019;26(11):1255-1262.

26. Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. *Eur Respir J.* 2005;26(5):948-968.

27. Quanjer PH, Stanojevic S, Cole TJ, et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the Global Lung Function 2012 equations. *Eur Respir J.* 2012;40(6):1324-1343.

28. Charlon T, Hong C, Sun J, et al. MAP: multimodal automated phenotyping. Published online 2024. https://cran.r-project.org/package=MAP

29. Boros PW, Franczuk M, Wesolowski S. Value of spirometry in detecting volume restriction in interstitial lung disease patients. *Respiration.* 2004;71(4):374-379.

30. Fortis S, Corazalla EO, Kim HJ. Does normal spirometry rule out an obstructive or restrictive ventilatory defect?. *Respir Investig.* 2017;55(1):55-57.

31. Hyatt RE, Cowl CT, Bjoraker JA, Scanlon PD. Conditions associated with an abnormal nonspecific pattern of pulmonary function tests. *Chest.* 2009;135(2):419-424.

32. Iyer VN, Schroeder DR, Parker KO, Hyatt RE, Scanlon PD. The nonspecific pulmonary function test: longitudinal follow-up and outcomes. *Chest.* 2011;139(4):878-886.

33. Knox-Brown B, Alexiou C, Stanojevic S, Sylvester KP. The utility of spirometry and single breath gas transfer measurements to identify low total lung capacity. *ERJ Open Res.* 2025;11(5):38-2025.

34. Gaffney AW, Himmelstein DU, Christiani DC, Woolhandler S. Socioeconomic inequality in respiratory health in the US from 1959 to 2018. *JAMA Intern Med.* 2021;181(7):968-976.

35. Ejike CO, Woo H, Galiatsatos P, et al. Contribution of individual and neighborhood factors to racial disparities in respiratory outcomes. *Am J Respir Crit Care Med.* 2021;203(8):987-997.

36. Schuyler AJ, Wenzel SE. Historical redlining impacts contemporary environmental and asthma-related outcomes in Black adults. *Am J Respir Crit Care Med.* 2022;206:824-837.

37. Baugh A, Thakur N. Race, racism, and respiratory health. *Clin Chest Med.* 2023;44(3):469-478.

38. Coates AL, Peslin R, Rodenstein D, Stocks J. Measurement of lung volumes by plethysmography. *Eur Respir J.* 1997;10(6):1415-1427.

39. Ruppel GL. What is the clinical value of lung volumes?. *Respir Care.* 2012;57(1):26-35.

40. Sylvester KP, Shakespeare J, Greening N. Lung volumes. *Clin Chest Med.* 2025;46(3):413-423.

41. Baugh AD, Shiboski S, Hansel NN, et al. Reconsidering the utility of race-specific lung function prediction equations. *Am J Respir Crit Care Med.* 2022;205(7):819-829.

42. Elmaleh-Sachs A, Balte P, Oelsner EC, et al. Race/ethnicity, spirometry reference equations, and prediction of incident clinical events: the Multi-Ethnic Study of Atherosclerosis (MESA) lung study. *Am J Respir Crit Care Med.* 2022;205(6):700-710.

43. McCormack MC, Balasubramanian A, Matsui EC, Peng RD, Wise RA, Keet CA. Race, lung function, and long-term mortality in the National Health and Nutrition Examination Survey III. *Am J Respir Crit Care Med.* 2022;205(6):723-724.

44. Moffett AT, Bowerman C, Stanojevic S, Eneanya ND, Halpern SD, Weissman GE. Global, race-neutral reference equations and pulmonary function test interpretation. *JAMA Netw Open.* 2023;6(6):e2316174.

45. Wan ES, Castaldi PJ, Cho MH, et al. Epidemiology, genetics, and subtyping of preserved ratio impaired spirometry (PRISm) in COPDGene. *Respir Res.* 2014;15(1):89.

46. Haneuse S, Arterburn D, Daniels MJ. Assessing missing data assumptions in EHR-based studies: a complex and underappreciated task. *JAMA Netw Open.* 2021;4(2):e210184.

Figure Legends

Figure 1

The association between FVC and FEV_1/FVC z-scores and restriction. Data are drawn from 83,886 PFTs performed at four pulmonary diagnostic labs between 2012 and 2025. Restriction is present if the TLC z-score is less than -1.645. Data are binned by z-score intervals of 0.2. The probability of restriction for a given bin is equal to the proportion of PFTs within that bin in which restriction is present. FVC z-scores are calculated using GLI Global reference equations while TLC z-scores are calculated using GLI 2019 equations. FEV_1 = forced expiratory volume in 1 second; FVC = forced vital capacity; PFT = pulmonary function test; TLC = total lung capacity.

Figure 2

Distribution of total lung capacity z-scores among patients with normal and abnormal forced vital capacities. Data are drawn from 83,886 PFTs performed at four pulmonary diagnostic labs between 2012 and 2025.

Figure 3

Changes in PFT interpretation on repeating testing. (A) An alluvial plot displays the PFT interpretations for 5,346 patients with restriction with normal spirometry present on their initial PFT. Strata within each axis represent the PFT interpretations for these patients on repeat testing. Alluvia between axes represent the interpretation of the preceding PFT. (B) A grid displays the probability of the PFT interpretation of a second PFT as a function of the PFT interpretation of the first PFT for 36,289 repeated PFTs. Rows display the interpretation of the first PFT while columns display the interpretation of the second PFT. PFT = pulmonary function test.

Table 1: Baseline Characteristics of Patients and Pulmonary Function Tests

				Restrictive			
	Normal	**Non-Specific**	**Obstructive**	**Normal Spirometry**	**Abnormal Spirometry**	**Mixed**	**All**
	($n = 33,283$)	($n = 2,128$)	($n = 15,886$)	($n = 11,361$)	($n = 17,194$)	($n = 4,034$)	($n = 83,886$)
Age, yr	57.5 (14.9)	61.6 (13.5)	60.3 (14.0)	60.5 (12.8)	58.9 (12.7)	56.7 (13.0)	58.8 (14.0)
Height, cm	167.1 (9.8)	164.5 (9.5)	167.6 (9.8)	167.8 (9.8)	168.6 (10.1)	169.2 (10.0)	167.7 (9.9)
Sex							
Male	11,839 (35.6%)	598 (28.1%)	6,854 (43.1%)	4,721 (41.6%)	7,721 (44.9%)	1,957 (48.5%)	33,690 (40.2%)
Female	21,444 (64.4%)	1,530 (71.9%)	9,032 (56.9%)	6,640 (58.4%)	9,473 (55.1%)	2,077 (51.5%)	50,196 (59.8%)
Race							
White	23,463 (74.3%)	962 (47.8%)	10,312 (67.6%)	6,306 (58.3%)	8,081 (49.3%)	1,735 (44.8%)	50,859 (63.6%)
Black	5,869 (18.6%)	919 (45.6%)	4,079 (26.7%)	3,722 (34.4%)	7,007 (42.7%)	1,899 (49.0%)	23,495 (29.4%)
Asian	1,094 (3.5%)	70 (3.5%)	366 (2.4%)	393 (3.6%)	686 (4.2%)	108 (2.8%)	2,717 (3.4%)
Other	1,163 (3.7%)	63 (3.1%)	505 (3.3%)	399 (3.7%)	619 (3.8%)	134 (3.5%)	2,883 (3.6%)
Ethnicity							
Hispanic	1,202 (3.7%)	55 (2.7%)	354 (2.3%)	424 (3.8%)	539 (3.2%)	126 (3.2%)	2,700 (3.3%)
Not Hispanic	31,134 (96.3%)	2,010 (97.3%)	15,144 (97.7%)	10,638 (96.2%)	16,167 (96.8%)	3,809 (96.8%)	78,902 (96.7%)
BMI, kg/m²	29.5 (7.1)	32.3 (9.0)	28.0 (6.9)	31.1 (7.3)	31.7 (8.2)	30.9 (7.8)	30.0 (7.6)
Pack Years, yr	8.7 (24.0)	12.0 (24.1)	23.1 (30.1)	12.1 (40.7)	10.7 (24.9)	17.7 (45.2)	12.5 (28.7)
Respiratory Symptoms							
Cough	5,722 (42.4%)	615 (56.1%)	3,238 (54.7%)	1,809 (50.6%)	4,988 (58.7%)	763 (56.7%)	17,135 (50.5%)
Dyspnea	5,905 (44.2%)	748 (68.4%)	3,805 (64.5%)	1,989 (55.8%)	6,106 (71.6%)	971 (71.8%)	19,524 (57.8%)
Wheeze	3,996 (29.7%)	607 (55.6%)	3,211 (54.5%)	1,105 (31.1%)	3,341 (39.6%)	750 (56.3%)	13,010 (38.6%)
Respiratory Disease							
Asthma	4,025 (12.5%)	401 (19.7%)	2,845 (18.6%)	1,158 (10.5%)	1,766 (10.7%)	719 (18.4%)	10,914 (13.5%)
Bronchiectasis	922 (2.9%)	101 (5.0%)	910 (6.0%)	234 (2.1%)	429 (2.6%)	167 (4.3%)	2,763 (3.4%)
Chest Wall Disorder	177 (0.5%)	35 (1.7%)	94 (0.6%)	48 (0.4%)	238 (1.4%)	40 (1.0%)	632 (0.8%)
Chronic Obstructive Pulmonary Disease	2,056 (6.4%)	528 (25.9%)	5,993 (39.3%)	809 (7.3%)	1,545 (9.4%)	882 (22.6%)	11,813 (14.6%)
Interstitial Lung Disease	5,488 (17.0%)	267 (13.1%)	2,072 (13.6%)	4,798 (43.6%)	7,818 (47.3%)	1,410 (36.1%)	21,853 (27.0%)
Neuromuscular Disease	430 (1.3%)	105 (5.2%)	108 (0.7%)	120 (1.1%)	230 (1.4%)	34 (0.9%)	1,027 (1.3%)
None	20,835 (64.7%)	867 (42.6%)	5,552 (36.4%)	4,881 (44.3%)	6,401 (38.7%)	1,410 (36.1%)	39,946 (49.3%)
Computed Tomography							
Chronic Obstructive Pulmonary Disease	2,942 (21.1%)	286 (34.8%)	4,497 (57.9%)	1,235 (20.1%)	1,629 (19.1%)	827 (37.1%)	11,416 (28.9%)
Interstitial Lung Disease	6,224 (44.6%)	306 (37.2%)	2,752 (35.4%)	4,363 (70.9%)	6,239 (73.2%)	1,360 (61.0%)	21,244 (53.8%)
Dynamic Lung Volumes, z-score							
FEV$_1$	−0.2 (0.9)	−2.3 (0.5)	−2.3 (1.2)	−1.0 (0.6)	−2.4 (0.7)	−3.0 (0.8)	−1.3 (1.4)
FVC	−0.0 (0.9)	−2.3 (0.7)	−0.7 (1.3)	−1.0 (0.4)	−2.6 (0.7)	−2.2 (1.0)	−1.0 (1.4)
FEV$_1$/FVC	−0.4 (0.8)	−0.5 (0.9)	−2.8 (0.9)	0.0 (0.9)	0.3 (1.1)	−2.5 (0.7)	−0.7 (1.4)
Static Lung Volumes, z-score							
TLC	−0.4 (0.8)	−0.8 (0.7)	0.2 (1.2)	−2.3 (0.5)	−3.4 (1.0)	−2.7 (0.9)	−1.3 (1.6)
RV	0.3 (0.9)	1.3 (1.0)	1.5 (1.4)	−1.1 (0.8)	−0.9 (1.0)	−0.3 (1.0)	0.1 (1.4)
Diffusing Capacity, z-score							
D$_{LCO}$	−0.7 (1.6)	−2.2 (2.0)	−2.4 (2.3)	−2.2 (1.6)	−3.4 (2.0)	−3.2 (1.9)	−1.9 (2.1)
K$_{CO}$	−0.3 (1.4)	−0.3 (1.8)	−1.5 (1.9)	−0.5 (1.6)	−0.5 (1.8)	−0.7 (1.8)	−0.6 (1.7)

Categorical data are presented as No. (%) while continuous data are represented as mean (SD). Missing data have been removed from both calculations. BMI = body mass index; D$_{LCO}$ = diffusing capacity for carbon monoxide; FEV$_1$ = forced expiratory volume in 1 second; FVC = forced vital capacity; K$_{CO}$ = transfer coefficient for carbon monoxide; RV = residual volume.

Table 2: Characteristics Associated with Restriction in Pulmonary Function Tests with Normal Spirometry

Characteristic	Unadjusted Odds Ratio (95% CI)	P Value	Adjusted[a] Odds Ratio (95% CI)	P Value
Age, yr	1.02 (1.01–1.02)	< 0.001	1.01 (1.01–1.01)	< 0.001
Sex				
Male	1.00 (Reference)	—	1.00 (Reference)	—
Female	0.78 (0.75–0.81)	< 0.001	0.64 (0.60–0.67)	< 0.001
Race				
White	1.00 (Reference)	—	1.00 (Reference)	—
Black	2.41 (2.29–2.53)	< 0.001	1.35 (1.26–1.43)	< 0.001
Asian	1.34 (1.19–1.51)	< 0.001	1.31 (1.13–1.52)	< 0.001
Other	1.28 (1.14–1.44)	< 0.001	1.25 (1.08–1.44)	0.003
Ethnicity				
Hispanic	1.00 (Reference)	—	1.00 (Reference)	—
Not Hispanic	0.97 (0.87–1.09)	0.596	0.81 (0.70–0.93)	0.003
BMI, kg/m²	1.03 (1.03–1.03)	< 0.001	1.00 (1.00–1.01)	0.011
Pack Years, yr	1.00 (1.00–1.00)	< 0.001	1.00 (1.00–1.00)	< 0.001
Respiratory Symptoms				
Cough	1.40 (1.30–1.51)	< 0.001	1.21 (1.11–1.33)	< 0.001
Dyspnea	1.61 (1.50–1.74)	< 0.001	1.15 (1.04–1.26)	0.004
Wheeze	1.07 (0.99–1.16)	0.079	0.84 (0.76–0.93)	< 0.001
Respiratory Diseases				
Asthma	0.83 (0.77–0.89)	< 0.001	0.79 (0.72–0.86)	< 0.001
Bronchiectasis	0.74 (0.64–0.85)	< 0.001	0.57 (0.48–0.68)	< 0.001
Chest Wall Disorder	0.81 (0.58–1.11)	0.199	0.55 (0.37–0.79)	0.002
Chronic Obstructive Pulmonary Disease	1.17 (1.08–1.28)	< 0.001	0.74 (0.67–0.82)	< 0.001
Interstitial Lung Disease	3.75 (3.57–3.93)	< 0.001	3.65 (3.43–3.88)	< 0.001
Neuromuscular Disease	0.84 (0.68–1.02)	0.085	0.64 (0.50–0.81)	< 0.001
None	0.43 (0.41–0.45)	< 0.001	0.52 (0.49–0.55)	< 0.001
Computed Tomography				
Chronic Obstructive Pulmonary Disease	0.94 (0.87–1.02)	0.119	0.81 (0.73–0.89)	< 0.001
Interstitial Lung Disease	3.02 (2.83–3.22)	< 0.001	3.02 (2.79–3.28)	< 0.001
Dynamic Lung Volumes				
FEV_1, z-score	0.24 (0.23–0.25)	< 0.001	2.03 (1.38–2.99)	< 0.001
FVC, z-score	0.10 (0.10–0.11)	< 0.001	0.05 (0.04–0.08)	< 0.001
FEV_1/FVC, z-score	1.81 (1.77–1.86)	< 0.001	1.10 (0.93–1.31)	0.268
Bronchodilator Response	0.45 (0.33–0.59)	< 0.001	0.38 (0.28–0.52)	< 0.001
Adequate Effort	0.61 (0.37–1.06)	0.071	0.83 (0.46–1.56)	0.557
Static Lung Volumes				
RV, z-score	0.11 (0.10–0.11)	< 0.001	0.01 (0.01–0.01)	< 0.001
Diffusing Capacity				
D_{LCO}, z-score	0.56 (0.55–0.57)	< 0.001	0.61 (0.60–0.62)	< 0.001
K_{CO}, z-score	0.91 (0.90–0.92)	< 0.001	0.81 (0.79–0.83)	< 0.001

Odds ratios compare the odds of a characteristic among PFTs with restriction with normal spirometry to the odds of the characteristic among PFTs with normal spirometry without restriction. Abbreviations: BMI = body mass index; D_{LCO} = diffusing capacity for carbon monoxide; FEV_1 = forced expiratory volume in 1 second; FVC = forced vital capacity; K_{CO} = transfer coefficient for carbon monoxide; PFT = pulmonary function test; RV = residual volume; V_A = alveolar volume.

[a]Adjusted for patient age, sex, FEV_1 z-score, FVC z-score, and FEV_1/FVC z-score.

Figure 1

Figure 2

Figure 3

B

Second Pulmonary Function Test

	Normal	Non-Specific	Obstructive	Restrictive with Normal Spirometry	Restrictive with Abnormal Spirometry	Mixed
Normal	**76.5%**	1.3%	8.0%	10.6%	2.6%	1.0%
Non-Specific	20.9%	**28.3%**	15.3%	5.3%	26.4%	3.9%
Obstructive	10.3%	1.0%	**81.4%**	1.3%	0.9%	5.1%
Restrictive with Normal Spirometry	18.8%	0.6%	1.5%	**62.9%**	13.6%	2.6%
Restrictive with Abnormal Spirometry	2.7%	2.5%	0.9%	8.8%	**80.3%**	4.7%
Mixed	2.8%	1.7%	15.6%	7.2%	16.5%	**56.0%**

First Pulmonary Function Test